Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIRx Med

Date Submitted: Mar 11, 2024
Date Accepted: Mar 11, 2024

The final, peer-reviewed published version of this preprint can be found here:

Authors’ Response to Peer Reviews of “Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis”

Makunts T, Joulfayan H, Abagyan R

Authors’ Response to Peer Reviews of “Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis”

JMIRx Med 2024;5:e58273

DOI: 10.2196/58273

PMID: 38738852

PMCID: 11090022

Author(s)’ Responses to Peer Review Reports

  • Tigran Makunts; 
  • Haroutyun Joulfayan; 
  • Ruben Abagyan

ABSTRACT

This is the author(s)’ responses to peer review reports related to MS ID55976


 Citation

Please cite as:

Makunts T, Joulfayan H, Abagyan R

Authors’ Response to Peer Reviews of “Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis”

JMIRx Med 2024;5:e58273

DOI: 10.2196/58273

PMID: 38738852

PMCID: 11090022

Per the author's request the PDF is not available.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.